

REMARKS/ARGUMENTS

ELECTION

The Examiner has repeated the assertion that the sequences of SEQ ID NO:4 and SEQ ID NO:6 represent different inventions. In particular, the Examiner states that the polypeptides do not share a common substantial structure or utility (March 19, 2008 Office Action, page 3).

Applicants timely traversed the restriction in the response submitted January 14, 2008, explaining that the two sequences represent variants of the same polypeptide. The "short form," *i.e.*, SEQ ID NO:6, is identical to SEQ ID NO:4 except for a deletion of 21 amino acids (positions 738-758 of SEQ ID NO:4). These polypeptides share the same essential structure, in that they share the functional actin-binding domain, and the unique C terminal domain found only in these prostate cancer-associated polypeptides (*see, e.g.*, paragraphs [0035] and [0040] of the specification, referring to the published application US20060160991). The unique C terminal domain of the polypeptides of both SEQ ID NO:4 and 6 and their unique, aberrant expression in prostate cancer make these polypeptides ideal diagnostic and therapeutic targets for prostate cancer.

However, in an effort to expedite prosecution, claim 1 is amended to exclude reference to SEQ ID NO:6, and claim 31 is canceled.

DECLARATION

The Examiner has objected to the original Declaration submitted November 28, 2005 for allegedly improper handwritten corrections in the document. Applicants made the corrections in the belief that they were in compliance with 37 CFR § 1.52(c). In an effort to expedite prosecution, however, Applicants submit herewith a new Combined Declaration and Power of Attorney.

PRIORITY

The Examiner has alleged that Applicants are not entitled to benefit from priority to U.S. Provisional Application 60/414,873, filed September 30, 2002, or the PCT Application PCT/JP03/12074, filed September 22, 2003. According to the Examiner, the provisional application does not include the polypeptide sequence of SEQ ID NO:4 or a nucleotide sequence that encodes the polypeptide. The Examiner concludes that Applicants are therefore entitled to the filing date of the present application, *i.e.*, November 23, 2005.

Applicants respectfully submit that the PCT application filed September 22, 2003 includes the sequence of SEQ ID NO:4. Applicants include **Exhibit A**, which includes the first page of WO04/031,231 and pages from the application showing SEQ ID NOs:3 and 4, *i.e.*, the nucleotide and polypeptide sequences of MICAL2-PV. Applicants therefore respectfully urge that the present claims are entitled to priority to the PCT application, filed September 22, 2003.

DRAWINGS

The Examiner has objected to the amino acid sequence depicted in Figure 1C without a sequence identifier. The Examiner requires Applicants to submit a corrected drawing sheet which includes the sequence identifier or, alternatively, to submit an amended description of the drawing, which includes the sequence identifier for the depicted sequence.

Applicants are selecting the option of submitting an amended description of the drawing, and therefore respectfully request withdrawal of the objection to Figure 1C.

SPECIFICATION

The Examiner has objected to the specification regarding: (1) reference to the amino acid sequence depicted in Figure 1C; (2) alleged improperly demarcated trademarks; and (3) allegedly improper embedded hyperlinks.

Applicants submit amended paragraphs to address each of these issues. As amended, paragraph [0034] (referring to the published application US 20060160991) explains that the sequence depicted in Figure 1C is SEQ ID NO:2. The remaining amended paragraphs

address the trademark and hyperlink issues, as well as minor typographical errors. Applicants therefore respectfully request withdrawal of the objections to the specification.

CLAIMS

Status of the claims

With entry of this amendment, claims 1 and 6 are pending. Claims 31 and 32 are canceled, and claim 1 is amended. Support for the amendments is found throughout the specification and drawings as originally filed, *e.g.*, in paragraphs [0040]-[0044] of the published application US 20060160991. Regarding the amino acid residues recited in amended claim 1, Applicants refer to **Exhibit B**, an alignment of the MICAL2-PV variants as described in the specification and sequence listing, which shows the recited amino acids from SEQ ID NO:4. No new matter is added.

Objection to the claims

The Examiner has objected to claims 1, 6, 31, and 32 as referring in the alternative to a non-elected invention. Solely in an effort to expedite prosecution, claim 1 is amended to remove reference to SEQ ID NO:6, and claims 31 and 32 are canceled. Accordingly, Applicants respectfully request withdrawal of the objection to the claims.

Rejection under 35 USC § 112, second paragraph

The Examiner has rejected claims 1, 6, 31, and 32 as allegedly indefinite for reciting the phrase "hybridizes under stringent conditions." The Examiner has also rejected claims 31 and 32 as allegedly indefinite for reciting the phrase "a pharmaceutically acceptable amount."

Solely in an effort to expedite prosecution, Applicants have removed the hybridization language from amended claim 1. Applicants have also canceled claims 31 and 32, rendering the second rejection moot. In so doing, Applicants make no admission as to the appropriateness of the rejection. In view of the amendments to the claims, Applicants respectfully request withdrawal of the rejection under the second paragraph of 35 USC § 112.

Rejections under 35 USC § 112, first paragraph - Written description

The Examiner has rejected claims 1, 6, 31, and 32 as allegedly failing to comply with the written description requirement. According to the Examiner, the specification only provides adequate description of the polypeptide of SEQ ID NO:4, because it allegedly fails to describe the structural and functional features of variants of SEQ ID NO:4 (*see* Office Action, page 12). To the extent to which the rejection applies to the amended claims, Applicants respectfully traverse.

Section 2163 of the MPEP sets forth the written description requirement as confirmed on multiple occasions by the Federal Circuit. The specification, drawings and claims as originally filed must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention.

The Revised Interim Written Description Guidelines, published March 25, 2008, provide examples of claims that comply with the written description requirement (*see* www.uspto.gov/web/menu/written.pdf). Example 10 analyzes a claim directed to variants of a protein that are at least 95% identical to a particular disclosed sequence and that have a particularly specified activity. The PTO concludes that "the genus of proteins that must be variants... does not have substantial variation since all the variants must possess the specific catalytic activity and must have at least 95% identity to the reference sequence." Thus, "the single species disclosed is representative of the genus because all members have at least 95% structural identity with the reference compound and because the presence of an assay which applicant provides for identifying all of the at least 95% identical variants... which are capable of the specified catalytic activity." Accordingly, "one skilled in the art would conclude that applicant was in possession of the necessary common attributes possessed by the members of the genus."

As amended, claim 1 part (b) is analogous to Example 10. Solely in an effort to expedite prosecution, claim 1 part (b) is amended to clarify both the structure and the function of the claimed polypeptides. In particular, the structure of variants of SEQ ID NO:4 includes

polypeptides with "ten or fewer amino acid substitutions, deletions, insertions, or additions." Functionally, the recited polypeptides bind actin and induce cell proliferation.

Amended part (b) is directed to an isolated nucleic acid having at least 98.9% identity to a reference sequence, namely, SEQ ID NO:4 (966/ 976 → 98.9%). Moreover, the function of actin binding and inducing cell proliferation is specified. Because the resulting species are defined in terms of both specific structure and function, the genus of polypeptides encompassed by the claim do not have substantial variation. Similar to Example 10, because the genus is not widely variable, the single species of SEQ ID NO:4 is sufficient to demonstrate possession.

Furthermore, as was the case in Example 10, the present specification sets forth assays for preparing an identifying such variants capable of actin binding and inducing cell proliferation. For example, paragraphs [0170]- [0181] describe detection of actin binding ability. Detection of cell proliferation can be detected by methods well known in the art, as described, for example, in paragraphs [0153]- [0160] and the Examples, paragraph [0260]. In addition, the specification provides methods of introducing mutations, *e.g.*, in paragraphs [0044]- [0052].

Regarding claim 1, part (c), Applicants submit that the recited polypeptide is described in the specification as filed. Paragraphs [0035], [0040], and [0258] and Figure 2 illustrate that the recited MICAL2-PV polypeptide variant has the same function as the polypeptide of SEQ ID NO:4. Applicants additionally provide **Ex. B**, which displays the amino acid residues of SEQ ID NO:4 included in the variant recited in part (c) of claim 1. Thus, the structure and function of the variant are specified sufficiently to meet the written description requirement.

In view of the foregoing remarks and amendments to the claims, Applicants respectfully request withdrawal of the rejection under the first paragraph of 35 USC § 112 for written description.

Rejection under 35 USC § 112, first paragraph - Enablement

The Examiner has rejected claims 1, 6, 31, and 32 as allegedly lacking enablement. According to the Examiner, the specification does enable making and using an

isolated polypeptide comprising the amino acid sequence of SEQ ID NO:4, an isolated nucleic acid molecule comprising a nucleotide sequence encoding said polypeptide, an isolated vector comprising said nucleotide sequence, and an isolated host cell comprising said vector. On page 17 of the Office Action, however, the Examiner alleges that the specification does not enable (1) the genus of polypeptides described in the claims or (2) use of the polypeptides to treat cancer (referring to claims 31 and 32). To the extent the rejection applies to the amended claims, Applicants respectfully traverse.

As explained in the MPEP at § 2164.01, the "test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation."

In an effort to expedite prosecution, claims 31 and 32 are canceled, and claim 1 is amended to clarify the genus of polypeptides included in claims 1 and 6. In so doing, Applicants make no admission regarding the appropriateness of the rejection.

Regarding the first aspect of the rejection, namely, that the specification does not provide guidance for the genus of polypeptides recited in the claims, Applicants submit that the claims as amended are enabled by the specification as filed. As explained above, amended claim 1 recites polypeptide variants of SEQ ID NO:4 with ten or fewer amino acid substitutions, deletions, insertions, or additions that bind actin and induce cell proliferation. Claim 1 also includes a variant of SEQ ID NO:4 comprising amino acids 1-737 and 759-976 of SEQ ID NO:4.

Given the present disclosure and knowledge in the art, one of skill could readily make and use the recited polypeptides. Methods of introducing sequence mutations are provided, *e.g.*, in paragraphs [0044]- [0052]. Methods of detecting the recited activities are provided, *e.g.*, in paragraphs [0153]- [0160] and the Examples (for inducing cell proliferation) and paragraphs [0170]- [0181] (for actin binding). Use of the claimed invention therefore would not constitute undue experimentation.

Regarding the second aspect of the rejection, Applicants submit that cancellation of claims 31 and 32 renders the issue moot. Accordingly, in view of the foregoing comments and claim amendments, Applicants respectfully request withdrawal of the rejection under the first paragraph of 35 USC § 112 for enablement.

Rejection under 35 USC § 102 - Ashida

The Examiner has rejected claims 1, 6, 31, and 32 as allegedly anticipated by Ashida, a UNIPROT sequence submitted February 15, 2005. The rejection is based on a priority date of November 28, 2005, asserted on page 5 of the Office Action.

As explained above under PRIORITY, Applicants submit that the present claims are entitled to a priority of the filing date of the PCT application, September 22, 2003. Accordingly, Ashida does not constitute prior art. Applicants therefore respectfully request withdrawal of the rejection under 35 USC § 102 based on Ashida.

Rejection under 35 USC § 102- Boehringer Mannheim Biochemicals catalog

The Examiner has rejected claims 31 and 32 as allegedly anticipated by the Boehringer Mannheim Biochemicals catalog from 1994, which discloses a kit with random primers. According to the Examiner, the random primer kit with all possible combinations of 6-nucleotide sequences anticipates a polynucleotide encoding a fragment of SEQ ID NO:4.

Solely in an effort to expedite prosecution, claims 31 and 32 are canceled. In so doing, Applicants make no admissions regarding the appropriateness of the rejection. In view of the cancellation of the rejected claims, Applicants respectfully request withdrawal of the rejection under 35 USC § 102.

CONCLUSION


In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.

Appl. No. 10/529,381
Amdt. dated June 18, 2008
Reply to Office Action of March 19, 2008

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Carol Johns
Reg. No. 50,463

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300

Attachments: Exhibits A and B
Declaration

KLB:cpj
61379945 v1

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 April 2004 (15.04.2004)

PCT

(10) International Publication Number
WO 2004/031231 A2

(51) International Patent Classification: C07K 14/47,
C12Q 1/68

(21) International Application Number:
PCT/JP2003/012074

(22) International Filing Date:
22 September 2003 (22.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/414,873 30 September 2002 (30.09.2002) US

(71) Applicants (for all designated States except US): ON-
COTHERAPY SCIENCE, INC. [JP/JP]; 3-16-13,
Shirokanedai, Minato-ku, Tokyo 108-0071 (JP). JAPAN
AS REPRESENTED BY THE PRESIDENT OF
THE UNIVERSITY OF TOKYO [JP/JP]; 3-1, Hongo
7-chome, Bunkyo-ku, Tokyo 113-8654 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NAKAMURA,
Yusuke [JP/JP]; 17-33, Azamino 1-chome, Aoba-ku,
Yokohama-shi, Kanagawa 225-0011 (JP). KATAGIRI,
Toyomasa [JP/JP]; 2-10-11-305, Higashigotanda, Shina-
gawa-ku, Tokyo 141-0022 (JP). NAKAGAWA, Hiideaki
[JP/JP]; 36-11-103, Kamiosaki 3-chome, Shinagawa-ku,
Tokyo 141-0021 (JP). NAKATSURU, Shuichi [JP/JP];
6-2, Shimoochiai 2-chome, Chuo-ku, Saitama-shi, Saitama
338-0002 (JP).

(74) Agents: SHIMIZU, Hatsushi et al.; Kantetsu Tsukuba
Bldg. 6F, 1-1-1, Oroschi-machi, Tsuchiura-shi, Ibaraki 300-
0847 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(III)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,
ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ,
UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,
PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(III)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO
patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG,
ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GENES AND POLYPEPTIDES RELATING TO PROSTATE CANCERS

(57) Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.

19 / 59

cagagcttca attagagoca tcattcatccc aggcagggat atctttgaga aatgactcag 6285

ttcagcccca ggccctgtg actctgotta aagcacacat ttctgtgtac tcttgtacct 6345

ggggcagcag gataatcacc aacacactct taacagagaaa caacacacca agcaccgtgg 6405

agctgtccta ggcaaacactc gcggtctcag gctgcggtgg gcgtctgtcc tgcattgtgc 6465

ccagaccacc ctgacccccg ggcctgcctg cctggccctg catgtgtcac gctcactgta 6525

tttgtgcaga tcttgccag tacaaagtcg ttgtctttgt cttatcttct cttacagagt 6585

ctccctccct ttatagaatg tcaaccaaag agtgcctcc tccctctetca gctctctctt 6645

tagctagcct ccccatctca tcacaacgca tgtctgtgac ctttgtaat catttacagt 6705

gccacacgga accctgtatt ttgcacacag caaaacaaac aatgtttagc tttatttatg 6765

gtatttgatg ctgtaaatgg aaataaatat tgttctttat 6805



<210> 4

<211> 976

<212> PRT

<213> Homo sapiens

20 / 59

<400> 4

Met Gly Glu Asn Glu Asp Glu Lys Gln Ala Gln Ala Gly Gln Val Phe

1

5

10

15

Glu Asn Phe Val Gln Ala Ser Thr Cys Lys Gly Thr Leu Gln Ala Phe

20

25

30

Asn Ile Leu Thr Arg His Leu Asp Leu Asp Pro Leu Asp His Arg Asn

35

40

45

Phe Tyr Ser Lys Leu Lys Ser Lys Val Thr Thr Trp Lys Ala Lys Ala

50

55

60

Leu Trp Tyr Lys Leu Asp Lys Arg Gly Ser His Lys Glu Tyr Lys Arg

65

70

75

80

Gly Lys Ser Cys Thr Asn Thr Lys Cys Leu Ile Val Gly Gly Gly Pro

85

90

95

Cys Gly Leu Arg Thr Ala Ile Glu Leu Ala Tyr Leu Gly Ala Lys Val

100

105

110

Val Val Val Glu Lys Arg Asp Ser Phe Ser Arg Asn Asn Val Leu His

115

120

125

21 / 59

Leu Trp Pro Phe Thr Ile His Asp Leu Arg Gly Leu Gly Ala Lys Lys

130

135

140

Phe Tyr Gly Lys Phe Cys Ala Gly Ser Ile Asp His Ile Ser Ile Arg

145

150

155

160

Gln Leu Gln Leu Ile Leu Phe Lys Val Ala Leu Met Leu Gly Val Glu

165

170

175

Ile His Val Asn Val Glu Phe Val Lys Val Leu Glu Pro Pro Glu Asp

180

185

190

Gln Glu Asn Gln Lys Ile Gly Trp Arg Ala Glu Phe Leu Pro Thr Asp

195

200

205

His Ser Leu Ser Glu Phe Glu Phe Asp Val Ile Ile Gly Ala Asp Gly

210

215

220

Arg Arg Asn Thr Leu Glu Gly Phe Arg Arg Lys Glu Phe Arg Gly Lys

225

230

235

240

Leu Ala Ile Ala Ile Thr Ala Asn Phe Ile Asn Arg Asn Ser Thr Ala

245

250

255

Glu Ala Lys Val Glu Glu Ile Ser Gly Val Ala Phe Ile Phe Asn Gln

260

265

270

22 / 59

Lys Phe Phe Gln Asp Leu Lys Glu Glu Thr Gly Ile Asp Leu Glu Asn

275

280

285

Ile Val Tyr Tyr Lys Asp Cys Thr His Tyr Phe Val Met Thr Ala Lys

290

295

300

Lys Gln Ser Leu Leu Asp Lys Gly Val Ile Ile Asn Asp Tyr Ile Asp

305

310

315

320

Thr Glu Met Leu Leu Cys Ala Glu Asn Val Asn Gln Asp Asn Leu Leu

325

330

335

Ser Tyr Ala Arg Glu Ala Ala Asp Phe Ala Thr Asn Tyr Gln Leu Pro

340

345

350

Ser Leu Asp Phe Ala Met Asn His Tyr Gly Gln Pro Asp Val Ala Met

355

360

365

Phe Asp Phe Thr Cys Met Tyr Ala Ser Glu Asn Ala Ala Leu Val Arg

370

375

380

Glu Arg Gln Ala His Gln Leu Leu Val Ala Leu Val Gly Asp Ser Leu

385

390

395

400

Leu Glu Pro Phe Trp Pro Met Gly Thr Gly Cys Ala Arg Gly Phe Leu

23 / 59

405

410

415

Ala Ala Phe Asp Thr Ala Trp Met Val Lys Ser Trp Asn Gln Gly Thr

420

425

430

Pro Pro Leu Glu Leu Leu Ala Glu Arg Glu Ser Leu Tyr Arg Leu Leu

435

440

445

Pro Gln Thr Thr Pro Glu Asn Ile Asn Lys Asn Phe Glu Gln Tyr Thr

450

455

460

Leu Asp Pro Gly Thr Arg Tyr Pro Asn Leu Asn Ser His Cys Val Arg

465

470

475

480

Pro His Gln Val Lys His Leu Tyr Ile Thr Lys Glu Leu Glu His Tyr

485

490

495

Pro Leu Glu Arg Leu Gly Ser Val Arg Arg Ser Val Asn Leu Ser Arg

500

505

510

Lys Glu Ser Asp Ile Arg Pro Ser Lys Leu Leu Thr Trp Cys Gln Gln

515

520

525

Gln Thr Glu Gly Tyr Gln His Val Asn Val Thr Asp Leu Thr Thr Ser

530

535

540

24/59

Trp Arg Ser Gly Leu Ala Leu Cys Ala Ile Ile His Arg Phe Arg Pro

545 550 555 560

Glu Leu Ile Asn Phe Asp Ser Leu Asn Glu Asp Asp Ala Val Glu Asn

565 570 575

Asn Gln Leu Ala Phe Asp Val Ala Glu Arg Glu Phe Gly Ile Pro Pro

580 585 590

Val Thr Thr Gly Lys Glu Met Ala Ser Ala Gln Glu Pro Asp Lys Leu

595 600 605

Ser Met Val Met Tyr Leu Ser Lys Phe Tyr Glu Leu Phe Arg Gly Thr

610 615 620

Pro Leu Arg Pro Val Asp Ser Trp Arg Lys Asn Tyr Gly Glu Asn Ala

625 630 635 640

Asp Leu Ser Leu Ala Lys Ser Ser Ile Ser Asn Asn Tyr Leu Asn Leu

645 650 655

Thr Phe Pro Arg Lys Arg Thr Pro Arg Val Asp Gly Gln Thr Gly Glu

660 665 670

Asn Asp Met Asn Lys Arg Arg Arg Lys Gly Phe Thr Asn Leu Asp Glu

675 680 685

25 / 59

Pro Ser Asn Phe Ser Ser Arg Ser Leu Gly Ser Asn Gln Glu Cys Gly

690

695

700

Ser Ser Lys Glu Gly Gly Asn Gln Asn Lys Val Lys Ser Met Ala Asn

705

710

715

720

Gln Leu Leu Ala Lys Phe Glu Glu Ser Thr Arg Asn Pro Ser Leu Met

725

730

735

Lys Gln Glu Lys Lys Ser Pro Ser Gly Phe His Phe His Pro Ser His

740

745

750

Leu Arg Thr Val His Pro Gln Glu Ser Met Arg Lys Ser Phe Pro Leu

755

760

765

Asn Leu Gly Gly Ser Asp Thr Cys Tyr Phe Cys Lys Lys Arg Val Tyr

770

775

780

Val Met Glu Arg Leu Ser Ala Glu Gly His Phe Phe His Arg Glu Cys

785

790

795

800

Phe Arg Cys Ser Ile Cys Ala Thr Thr Leu Arg Leu Ala Ala Tyr Thr

805

810

815

Phe Asp Cys Asp Glu Gly Lys Phe Tyr Cys Lys Pro His Phe Ile His

26 / 59

820

825

830

Cys Lys Thr Asn Ser Lys Gln Arg Lys Arg Arg Ala Glu Leu Lys Gln

835

840

845

Gln Arg Glu Glu Glu Ala Thr Trp Gln Glu Gln Glu Ala Pro Arg Arg

850

855

860

Asp Thr Pro Thr Glu Ser Ser Cys Ala Val Ala Ala Ile Gly Thr Leu

865

870

875

880

Glu Gly Ser Pro Pro Gly Ile Ser Thr Ser Phe Phe Arg Lys Val Leu

885

890

895

Gly Trp Pro Leu Arg Leu Pro Arg Asp Leu Cys Asn Trp Met Gln Gly

900

905

910

Leu Leu Gln Ala Ala Gly Leu His Ile Arg Asp Asn Ala Tyr Asn Tyr

915

920

925

Cys Tyr Met Tyr Glu Leu Leu Ser Leu Gly Leu Pro Leu Leu Trp Ala

930

935

940

Phe Ser Glu Val Leu Ala Ala Met Tyr Arg Glu Ser Glu Gly Ser Leu

945

950

955

960

27 / 59

Glu Ser Ile Cys Asn Trp Val Leu Arg Cys Phe Pro Val Lys Leu Arg

965

970

975

<210> 5

<211> 6742

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (265).. (3132)

<223>

<400> 5

ccgggccgcc tcgtctgctc ccagctctgt cagtggcccg cggggcccca tcgtgcgcc 60

cggggccagg gccgaggcag gcctgaccgg ggcccgggca gcccgccga ctttcggaac 120

atggcaacc gtgtgtgtct catccagaa agagaagact ttaaccactg tgatgctga 180

gaatecagtg tgacgtttct ccagatactt catgtgttc acctgtgtcc tcgccgcacc 240

actgccgcac acgactcctg aacc atg ggg gaa aac gag gat gag aag cag 291

Met Gly Glu Asn Glu Asp Glu Lys Gln

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.18 [Mar-02-2008]


Matrix **BLOSUM62** gap open: **11** gap extension: **1**
 x_dropoff: **0** expect: **10.00** wordsize: **3** ☒ Filter ☐ View option **Standard**
 Masking character option **X for protein, n for nucleotide** Masking color option **Black**
☐ Show CDS translation **Align**

Sequence 1: MICAL2PV_long_NO4

Length = 976 (1 .. 976)

Sequence 2: MICAL2PV_short_NO6

Length = 955 (1 .. 955)



NOTE: Bitscore and expect value are calculated based on the size of the nr database.

Score = 1945 bits (5038), Expect = 0.0

Identities = 955/976 (97%), Positives = 955/976 (97%), Gaps = 21/976 (2%)

Query	1	MGENEDEKQAQAGQVFENFVQASTCKGTLQAFNILTRHLDLDPLDHRNFYSKLSKSVTTW	60
Sbjct	1	MGENEDEKQAQAGQVFENFVQASTCKGTLQAFNILTRHLDLDPLDHRNFYSKLSKSVTTW	60
Query	61	KAKALWYKLDKRGSHKEYKRGKSCNTKCLIVGGGPCGLRTAIELAYLGAKVVVVEKRD	120
Sbjct	61	KAKALWYKLDKRGSHKEYKRGKSCNTKCLIVGGGPCGLRTAIELAYLGAKVVVVEKRD	120
Query	121	FSRNNVLHLWPFTIHDRLGLGAKKFYKFCAGSIDHISIRQLQLILFKVALMLGVEIHVN	180
Sbjct	121	FSRNNVLHLWPFTIHDRLGLGAKKFYKFCAGSIDHISIRQLQLILFKVALMLGVEIHVN	180
Query	181	VEFVKVLEPPEDQENQKIGWRAEFLPTDHSLSSEFDFVIIGADGRRNTLEGFRFRKEFRGK	240

		VEFVKVLEPPEDQENQKIGWRAEFLPTDHSLSSEFEFDVIGADGRRNTLEGFRKREFRGK	
Sbjct	181	VEFVKVLEPPEDQENQKIGWRAEFLPTDHSLSSEFEFDVIGADGRRNTLEGFRKREFRGK	240
Query	241	LAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYKDCETHYFV	300
Sbjct	241	LAIAITANFINRNSTAEAKVEEISGVAFIFNQKFFQDLKEETGIDLENIVYKDCETHYFV	300
Query	301	MTAKKQSLLDKGVIINDYIDTEMLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAMNH	360
Sbjct	301	MTAKKQSLLDKGVIINDYIDTEMLLCAENVNQDNLLSYAREAADFATNYQLPSLDFAMNH	360
Query	361	YGQPDVAMFDFTCMYASENAALVRERQAHQLLVALVGDSLLEFFWPMGTGCARGFLAAFD	420
Sbjct	361	YGQPDVAMFDFTCMYASENAALVRERQAHQLLVALVGDSLLEFFWPMGTGCARGFLAAFD	420
Query	421	TAWMVKSWNQGTTPLELLAERESLYRLLPQTTPENINKNFQYTLDPGTRYPNLNSHCVR	480
Sbjct	421	TAWMVKSWNQGTTPLELLAERESLYRLLPQTTPENINKNFQYTLDPGTRYPNLNSHCVR	480
Query	481	PHQVKHLYITKELEHYPLERLGSVRRSVNLSRKESDIRPSKLLTWCQQQTEGYQHVNVD	540
Sbjct	481	PHQVKHLYITKELEHYPLERLGSVRRSVNLSRKESDIRPSKLLTWCQQQTEGYQHVNVD	540
Query	541	LTTSWRSGALCAIHRFPRELINFDLSNEDDAVENNQALAFDVAEREFGIPPVTTGKEMA	600
Sbjct	541	LTTSWRSGALCAIHRFPRELINFDLSNEDDAVENNQALAFDVAEREFGIPPVTTGKEMA	600
Query	601	SAQEPDKLSMVMYLSKFYELFRGTPLRPVDSWRKNYGENADLSLAKSSISNNYLNLTFFPR	660
Sbjct	601	SAQEPDKLSMVMYLSKFYELFRGTPLRPVDSWRKNYGENADLSLAKSSISNNYLNLTFFPR	660
Query	661	KRTPRVGDQGTENDMNKRRRKGFNTLDEPSNFSRSLGSNQECGSSKEGGNQNKVKSMA	720
Sbjct	661	KRTPRVGDQGTENDMNKRRRKGFNTLDEPSNFSRSLGSNQECGSSKEGGNQNKVKSMA	720
Query	721	QLLAKFEESTRNPSLMKQEKKSPSGFHFHPSHLRTVHPQESMRKSFPNLNGSDTCYFCK	780
Sbjct	721	QLLAKFEESTRNPSLMK-----QESMRKSFPNLNGSDTCYFCK	759
Query	781	KRVYVMERLSAEGHFFHRECFCRCSICATTLRLAAYTFDCDEGKFYCKPHFIHCKTNSKQR	840
Sbjct	760	KRVYVMERLSAEGHFFHRECFCRCSICATTLRLAAYTFDCDEGKFYCKPHFIHCKTNSKQR	819
Query	841	KRRAELKQREEEATWQEQEAPRRDTPTESSCAVAAGTLEGSPPGISTSFFRKVLGWPL	900
Sbjct	820	KRRAELKQREEEATWQEQEAPRRDTPTESSCAVAAGTLEGSPPGISTSFFRKVLGWPL	879
Query	901	RLPRDLCNMWQGLLQAAGLHIRDNAYNYCYMYELLSLGLPLLWAFSEVLAAMYRESEGS	960
Sbjct	880	RLPRDLCNMWQGLLQAAGLHIRDNAYNYCYMYELLSLGLPLLWAFSEVLAAMYRESEGS	939
Query	961	ESICNWVLRCPFVKLR	976

ESICNWVLRCFPVKLR
Sbjct 940 ESICNWVLRCFPVKLR 955

CPU time: 0.06 user secs. 0.04 sys. secs 0.10 total secs.